Form 8-K
8-K — PDS Biotechnology Corp
Accession: 0001140361-26-032947
Filed: 2026-08-14
Period: 2026-08-10
CIK: 0001472091
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item: Submission of Matters to a Vote of Security Holders
Item: Financial Statements and Exhibits
Documents
8-K — ef20080184_8k.htm (Primary)
EX-3.1 — EXHIBIT 3.1 (ef20080184_ex3-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: ef20080184_8k.htm · Sequence: 1
false12-310001472091NASDAQ00014720912026-08-102026-08-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
August 10, 2026
Date of Report (Date of earliest event reported)
PDS Biotechnology Corporation
(Exact name of registrant
as specified in its charter)
Delaware
001-37568
26-4231384
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
303A College Road East
Princeton, NJ
08540
(Address of Principal Executive Offices)
(Zip Code)
(800) 208-3343
Registrant’s telephone number, including area code
(Former name or former address if changed since last report,)
Securities registered pursuant to Section 12 (b) of the Act:
Title of each class:
Trading Symbol(s)
Name of each exchange on which
registered:
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Stock Market LLC
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
PDS Biotechnology Corporation (the “Company”) held its 2026 annual meeting of stockholders on August 10, 2026 (the “Annual
Meeting”). As previously disclosed, on June 15, 2026, the Board of Directors of the Company adopted, subject to stockholder approval, an amendment (the “Amendment”) to the Eighth Amended and Restated Certificate of Incorporation of the Company (as
amended, the “Charter”). The stockholders voted to approve the Amendment at the Annual Meeting. The Amendment increased the number of shares of authorized common stock, par value $0.00033 per share, of the Company from 150,000,000 to 300,000,000
shares. The Charter remains unchanged in all other respects. The foregoing description of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1
hereto and is incorporated by reference herein.
Item 5.07
Submission of Matters to a Vote of Security Holders.
At the Annual Meeting, the following proposals were submitted to the stockholders of the Company:
Proposal 1:
A proposal to elect two Class B directors of the Company, Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D., each to hold office until the 2029 Annual Meeting of
Stockholders or until their successors shall have been duly elected and qualified.
Proposal 2:
A proposal to approve the Amendment.
Proposal 3:
A proposal to ratify the appointment of KPMG US LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31,
2026.
Proposal 4:
A proposal to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers.
For more information about the foregoing proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the
United States Securities and Exchange Commission on June 26, 2026. Of the 55,815,653 shares of the Company’s common stock entitled to vote at the Annual Meeting, 31,594,722 shares, or approximately 56.60%, were represented at the Annual Meeting in
person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below.
Proposal 1:
Election of Class B Directors.
The Company’s stockholders elected the following directors to serve as Class B directors until the 2029 Annual Meeting of Stockholders
of the Company or until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows:
Director
Votes For
Votes Withheld
Broker Non-Votes
Kamil Ali-Jackson, J.D.
8,986,360
3,280,808
19,327,554
Ilian Iliev, Ph.D.
9,409,728
2,857,440
19,327,554
Proposal 2:
Approval of the Amendment.
The Company’s stockholders voted to approve the Amendment. The votes regarding this proposal were as follows:
Votes For
Votes Against
Votes Abstaining
Broker Non-Votes
19,904,111
11,545,436
145,175
0
Proposal 3:
Ratification of Appointment KPMG US LLP.
The Company’s stockholders ratified the appointment of KPMG US LLP as the Company’s independent registered public accounting firm for
the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:
Votes For
Votes Against
Votes Abstaining
Broker Non-Votes
30,351,424
520,018
723,280
0
Proposal 4:
Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers.
The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers.
The votes regarding this proposal were as follows:
Votes For
Votes Against
Votes Abstaining
Broker Non-Votes
7,237,690
3,960,228
1,069,250
19,327,554
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
3.1
Amendment to the Eighth Amended and Restated Certificate of Incorporation, as amended.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
PDS Biotechnology Corporation
Date: August 14, 2026
By:
/s/ Frank Bedu-Addo, Ph.D.
Name: Frank Bedu-Addo, Ph.D.
Title: President and Chief Executive Officer
EX-3.1 — EXHIBIT 3.1
EX-3.1
Filename: ef20080184_ex3-1.htm · Sequence: 2
Exhibit 3.1
CERTIFICATE OF AMENDMENT
TO THE
EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State
of Delaware (the “Corporation”),
DOES HEREBY CERTIFY THAT:
FIRST: The name of the Corporation is PDS
Biotechnology Corporation.
SECOND: The Board of Directors of the
Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Eighth Amended and Restated Certificate of Incorporation, as amended, as
follows:
Subsection (a) of ARTICLE IV – CAPITALIZATION shall be deleted in its entirety and the following shall be inserted in lieu thereof:
“(a) Authorized Shares. The total
number of shares of stock which the Corporation shall have authority to issue is 305,000,000 consisting of 300,000,000 shares of Common Stock, par value $0.00033 per share (“Common
Stock”), and Five Million (5,000,000) shares of Preferred Stock, par value $0.00033 per share (“Preferred Stock”). Such stock may be issued from time to
time by the Corporation for such consideration as may be fixed by the board of directors of the Corporation (the “Board of Directors”). Except as otherwise provided by
law, the shares of stock of the Corporation, regardless of class, may be issued by the Corporation from time to time in such amounts, for such consideration and for such corporate purposes as the Board of Directors may from time to time determine.”
THIRD: That this Certificate of Amendment
was submitted to the stockholders of the Corporation for their approval and was duly adopted at an Annual Meeting of Stockholders held on August 10, 2026, in accordance with the provisions of Section 242 of the General Corporation Law of the State
of Delaware.
FOURTH: All other provisions of the Eighth
Amended and Restated Certificate of Incorporation shall remain in full force and effect.
FIFTH: That this Certificate of Amendment
to the Eighth Amended and Restated Certificate of Incorporation shall be effective upon filing.
IN WITNESS WHEREOF, the undersigned has
executed this Certificate of Amendment as of the 10th day of August, 2026.
PDS BIOTECHNOLOGY CORPORATION
By: /s/ Frank Bedu-Addo
Name: Frank Bedu-Addo, Ph.D.
Title: President and Chief Executive Officer
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Document and Entity Information
Aug. 10, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 10, 2026
Current Fiscal Year End Date
--12-31
Entity File Number
001-37568
Entity Registrant Name
PDS Biotechnology Corporation
Entity Central Index Key
0001472091
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
26-4231384
Entity Address, Address Line One
303A College Road East
Entity Address, City or Town
Princeton
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
08540
City Area Code
800
Local Phone Number
208-3343
Title of 12(b) Security
Common Stock, par value $0.00033 per share
Trading Symbol
PDSB
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details
Name:
dei_CurrentFiscalYearEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:gMonthDayItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration